Nautilus Biotechnology is trading at $2.81, up 10.00%, amid stronger biotech-sector sentiment.
- No company-specific announcement explaining the October 21 move surfaced; the company’s latest release scheduled Q3 results for October 27.
- XBI was up 2.10%, alongside biotech M&A and positive clinical-trial news.
- Broad-market indices were also higher, though biotech was the stronger available explanation.